Filing summary
Registrant identity: The request identifies Tectonic Therapeutic, Inc., but the supplied Form 10-Q is for AVROBIO, Inc. This summary reflects the supplied filing, not Tectonic Therapeutic.
Business context and reporting period
AVROBIO is a clinical-stage gene therapy company developing single-dose hematopoietic stem cell gene therapies for rare diseases. This unaudited 10-Q covers the quarter and six months ended June 30, 2022; it was filed August 9, 2022. The company had no product revenue. Its five programs were cystinosis, Gaucher disease types 1 and 3, Hunter syndrome, and Pompe disease; two were in clinical development.
Financial results and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $18.9 million | $22.5 million | $38.1 million | $41.0 million |
| General and administrative expense | $8.9 million | $8.8 million | $19.1 million | $17.2 million |
| Net loss | $28.1 million | $31.4 million | $57.9 million | $58.3 million |
| Basic and diluted loss per share | $0.64 | $0.74 | $1.32 | $1.39 |
| Cash used in operating activities | Not separately stated | Not separately stated | $57.1 million | $47.3 million |
At June 30, 2022, cash and cash equivalents were $132.4 million, plus $0.5 million restricted cash. Current assets were $142.1 million and current liabilities $12.8 million. The company reported total liabilities of $27.9 million and stockholders’ equity of $118.3 million. The term loan had $15.0 million principal outstanding and a $15.1 million net carrying value; it is secured by substantially all assets other than intellectual property. No revenue-based margins are meaningful because the company had no product sales.
Changes versus prior comparable periods
- Q2 operating expenses fell $3.6 million year over year, mainly because R&D expense declined $3.7 million; G&A was broadly unchanged. Net loss narrowed by $3.3 million.
- For the first half, total operating expenses decreased $1.1 million, but cash used in operations increased $9.8 million year over year, reflecting operating asset and liability movements and non-cash adjustments.
- Cash and cash equivalents declined $57.2 million from December 31, 2021. The accumulated deficit increased to $441.4 million.
- Fabry-related R&D expense decreased, while cystinosis R&D rose to $3.7 million for the first half. Clinical trial consulting expense contributed to the year-over-year increase in R&D costs in some areas.
Outlook, management commentary, risks and unusual items
- Management estimated that June 30 cash would fund operating expenses and capital spending into the first quarter of 2024. The filing cautions that this forecast depends on assumptions and that capital could be exhausted sooner. The notes separately state cash is expected to cover at least the next 12 months from the filing date.
- AVR-RD-01 for Fabry disease was deprioritized in January 2022 after variable engraftment patterns appeared in five recently dosed Phase 2 patients, including concerning enzyme activity and vector-copy-number reductions in three. Phase 2 enrollment stopped; the company shifted focus to other programs.
- The Fabry decision also eliminated access to $20.0 million of milestone-contingent loan funding. A further $15.0 million tranche requires lender approval; an additional $15.0 million under the first tranche remained available subject to loan terms.
- A workforce reduction of approximately 23% followed the Fabry reprioritization. The company recorded $1.4 million of first-half restructuring expense, all of which had been paid by June 30.
- Management expected to provide updated Gaucher type 1 interim data in Q4 2022; planned a company-sponsored cystinosis trial in 2023, subject to FDA interactions; and anticipated potential 2023 collaborator-sponsored trials for Gaucher type 3 and Hunter syndrome, subject to regulatory progress. The company no longer expected to start a Pompe trial in 2023.
- Key risks include clinical efficacy and safety uncertainty, gene-therapy conditioning and engraftment risks, patient enrollment and COVID-19 disruptions, manufacturing and sole-source supplier dependence, regulatory delays, competition, intellectual-property exposure, and the need for additional financing. The company has never generated product revenue and expects continued losses.
- The filing reports no material pending or threatened litigation. Management concluded disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2022.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is AVROBIO, Inc., not Tectonic Therapeutic, Inc.
- Review subsequent clinical updates, particularly whether the Fabry engraftment findings have implications for other programs and the status of Gaucher and cystinosis trials.
- Assess the cash-runway estimate against actual spending, financing needs, and the assumptions behind the differing runway statements in the filing.
- Verify availability and conditions for any remaining loan drawdowns, including lender consent, covenants, interest costs, and repayment obligations.
- Track program timelines, manufacturing comparability and supply arrangements, and any regulatory or safety developments that could delay trials or increase costs.